Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Treatment Strategies for Psychological Disorders

Treatment Strategies for Psychological Disorders

Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Serum Amyloid β Oligomer May Predict Treatment Response in Middle-Aged and Late-Life Patients With Depression.

Neuropsychopharmacology reports·2026

Same author

Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis.

Neuropsychopharmacology reports·2025

Same author

Neuroaxonal damage as a mechanism underlying late-life depression.

Psychiatry and clinical neurosciences·2024

Same author

Guidelines for diagnosis and treatment of depression in older adults: A report from the Japanese Society of mood disorders.

Psychiatry and clinical neurosciences·2022

Same author

Serum levels and mutual correlations of amyloid β in patients with depression.

Geriatrics & gerontology international·2019

Search research articles

Related Experiment Video

Updated: Jun 24, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Treatment strategy for late-life depression.

Hajime Baba^1,2

¹Department of Psychiatry, Faculty of Medicine, Juntendo Koshigaya Hospital Juntendo University Saitama Japan.

PCN Reports : Psychiatry and Clinical Neurosciences

|June 13, 2024

Summary

Late-life depression (LLD) management is complex due to diagnostic challenges and poorer treatment response in older adults. Tailored, patient-specific interventions, including psychotherapy and newer antidepressants, are crucial for effective LLD care.

Keywords:

antidepressant depression elderly late‐life treatment

More Related Videos

Animal Models of Depression - Chronic Despair Model CDM

Animal Models of Depression - Chronic Despair Model CDM

Published on: September 23, 2021

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Related Experiment Videos

Last Updated: Jun 24, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Animal Models of Depression - Chronic Despair Model CDM

Animal Models of Depression - Chronic Despair Model CDM

Published on: September 23, 2021

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Area of Science:

Geriatrics
Psychiatry
Neuroscience

Background:

Global population aging is increasing the incidence of late-life depression (LLD).
LLD presents unique challenges in diagnosis and treatment compared to early-adult depression.
Accurate diagnosis requires differentiating LLD from dementia, delirium, and other medical conditions.

Purpose of the Study:

To review current management and treatment strategies for late-life depression.
To highlight the complexities and specific considerations for treating depression in older adults.
To outline evidence-based approaches for LLD based on treatment response levels.

Main Methods:

Review of existing literature on late-life depression diagnosis and treatment.
Analysis of treatment strategies, including psychotherapy, pharmacotherapy, and neuromodulation.
Categorization of further-line treatment based on first-line response.

Main Results:

LLD is characterized by poorer treatment response and higher recurrence rates than in younger populations.
Psychosocial interventions, cognitive behavioral therapy, and problem-solving therapy show efficacy.
Newer antidepressants are recommended, with careful monitoring for adverse events; neuromodulation is also beneficial.

Conclusions:

Late-life depression is highly heterogeneous, necessitating individualized treatment plans.
Treatment strategies must consider the patient's background, condition, and response to initial therapies.
Personalized, multi-faceted approaches are essential for optimizing outcomes in LLD patients.